D-0033-2026 Class III Ongoing
FDA drug recall D-0033-2026 was initiated by JB Chemicals And Pharmaceuticals Ltd on Sep 12, 2025 and is designated Class III. Reason for recall: Tablet/Capsules Imprinted with Wrong ID The recall status is ongoing. Affected quantity: 13,440 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 29, 2025
- Initiation Date
- Sep 12, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 13,440 bottles
Product description
Cetirizine Hydrochloride Tablets USP 10 mg, 500 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-50
Reason for recall
Tablet/Capsules Imprinted with Wrong ID
Distribution pattern
U.S. Nationwide
Code information
Lot # PY925014, PY925013, Exp. 1/31/2028
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0033-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026